This company listing is no longer active
IceCure Medical Management
Management criteria checks 2/4
IceCure Medical's CEO is Eyal Shamir, appointed in Sep 2016, he has a tenure of 6.83 years. His total yearly compensation is $658.24K , comprised of 71% salary and 29% bonuses, including company stock and options. He directly owns 1.06% of the company’s shares, worth ₪2.06M. The average tenure of the management team and the board of directors is 4.6 years and 5.6 years respectively.
Key information
Eyal Shamir
Chief executive officer
US$658.2k
Total compensation
| CEO salary percentage | 71.0% |
| CEO tenure | 6.8yrs |
| CEO ownership | 1.1% |
| Management average tenure | 4.6yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
Will IceCure Medical (TLV:ICCM) Spend Its Cash Wisely?
Jul 13
Here's Why We're Watching IceCure Medical's (TLV:ICCM) Cash Burn Situation
Mar 29Are Investors Undervaluing IceCure Medical Ltd (TLV:ICCM) By 29%?
Sep 06Is IceCure Medical Ltd (TLV:ICCM) Potentially Undervalued?
Mar 03Is IceCure Medical (TLV:ICCM) In A Good Position To Deliver On Growth Plans?
Dec 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$658k | US$467k | -US$17m |
| Sep 30 2022 | n/a | n/a | -US$16m |
| Jun 30 2022 | n/a | n/a | -US$15m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$489k | US$426k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$6m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$420k | US$370k | -US$4m |
| Sep 30 2020 | n/a | n/a | -US$4m |
| Jun 30 2020 | n/a | n/a | -US$4m |
| Mar 31 2020 | n/a | n/a | -US$4m |
| Dec 31 2019 | n/a | n/a | -US$5m |
| Sep 30 2019 | n/a | n/a | -US$5m |
| Jun 30 2019 | n/a | n/a | -US$4m |
| Mar 31 2019 | n/a | n/a | -US$4m |
| Dec 31 2018 | US$350k | US$251k | -US$4m |
| Sep 30 2018 | n/a | n/a | -US$3m |
| Jun 30 2018 | n/a | n/a | -US$3m |
| Mar 31 2018 | n/a | n/a | -US$3m |
| Dec 31 2017 | US$312k | US$259k | -US$3m |
Compensation vs Market: Eyal's total compensation ($USD658.24K) is above average for companies of similar size in the IL market ($USD450.00K).
Compensation vs Earnings: Eyal's compensation has increased whilst the company is unprofitable.
CEO
Eyal Shamir (62 yo)
6.8yrs
Tenure
US$658,237
Compensation
Mr. Eyal Shamir serves as Chief Executive Officer and Director at IceCure Medical Ltd. since September 2016 and December 2017 respectively. Mr. Shamir served as Chief Executive Officer of Tadbik Pack Ltd.,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$658.24k | 1.06% ₪ 2.1m | |
| CFO & COO | 6.2yrs | US$474.89k | 0.58% ₪ 1.1m | |
| Vice President of Business Development & Global Marketing | 4.6yrs | US$380.37k | 0.26% ₪ 497.3k | |
| Vice President of Human Resources | 1.7yrs | US$282.17k | 0.044% ₪ 85.8k | |
| Vice President of Operations & Service | less than a year | no data | 0.074% ₪ 143.8k |
4.6yrs
Average Tenure
54yo
Average Age
Experienced Management: ICCM's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.6yrs | US$658.24k | 1.06% ₪ 2.1m | |
| Independent Director | 10.9yrs | no data | no data | |
| Independent External Director | 3.8yrs | US$205.58k | no data | |
| Independent External Director | 9.9yrs | no data | no data | |
| Chairman of the Board | 5.6yrs | US$62.23k | 0.37% ₪ 724.4k | |
| Independent Director | less than a year | no data | no data | |
| Director | 3.3yrs | no data | 0.086% ₪ 167.0k |
5.6yrs
Average Tenure
60yo
Average Age
Experienced Board: ICCM's board of directors are considered experienced (5.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/07/25 09:11 |
| End of Day Share Price | 2023/07/20 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IceCure Medical Ltd is covered by 3 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Kemp Dolliver | Brookline Capital Markets |
| Yi Chen | H.C. Wainwright & Co. |
| Anthony Vendetti | Maxim Group |